* Avanos Medical Inc AVNS.N AVNS.K is expected to show a
rise
in quarterly revenue when it reports results on February 21.
* The Alpharetta Georgia-based company is expected to
report a
12.4% increase in revenue to $217.3 million from $193.4 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Avanos Medical Inc
is for
earnings of 49 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Avanos
Medical
Inc is $26, below its last closing price of $30.05.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 0.35 0.35 0.38 Beat 7.8
Jun. 30 2022 0.38 0.38 0.41 Beat 7.3
Mar. 31 2022 0.26 0.26 0.26 Met 0
Dec. 31 2021 0.40 0.40 0.46 Beat 14.4
Sep. 0.29 0.30 0.25 Missed -17.1
30 2021
Jun. 30 2021 0.23 0.23 0.21 Missed -10
Mar. 31 2021 0.18 0.19 0.23 Beat 24.3
Dec. 31 2020 0.22 0.22 0.28 Beat 29.2
This summary was machine generated February 17 at 13:52 GMT.
All figures in US dollars unless otherwise stated